Raising awareness for the cancer chordoma.

Bill: 117-hres-1514
Sponsor: full_name: Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4]
Introduced: 2022-12-08
Policy area: Health
Latest action: action_date: 2022-12-13
text: Sponsor introductory remarks on measure. (CR H9706)

Summaries:
action_date: 2022-12-08
action_desc: Introduced in House
text: <p>This resolution expresses the sense of the House of Representatives of the need for increased funding and support for diagnosis, treatments, and cures for chordoma (a bone cancer of the skull and spine).</p>

tv_txt: IV 117th CONGRESS 2d Session H. RES. 1514 IN THE HOUSE OF REPRESENTATIVES December 8, 2022 Mr. Johnson of Georgia (for himself, Mr. Higgins of New York , Mr. Fitzpatrick , Mr. Kilmer , Mr. Thompson of Mississippi , and Ms. Williams of Georgia ) submitted the following resolution; which was referred to the Committee on Energy and Commerce RESOLUTION Raising awareness for the cancer chordoma.

Whereas chordoma is a slow growing, yet aggressive bone cancer of the skull and spine; Whereas it strikes people of all ages and affects more than 25,000 individuals worldwide; Whereas each year, thousands of people are diagnosed with chordoma including about 300 people annually in the United States; Whereas chordomas are among the most complicated tumors to treat due to involvement of critical structures such as the brain stem, spinal cord, and important nerves and arteries; Whereas surgery or radiation performed by a skilled treatment team can be curative for some patients, but even with the best care possible, the recurrence rate remains high; and Whereas no drugs are known to cure or effectively control the disease, meaning that patients whose disease progresses after exhausting surgical and radiation options have little hope for a full recovery: Now, therefore, be it

That it is the sense of the House of Representatives that chordoma patients and families need increased funding and support for— (1) accurate and early diagnosis; (2) the development of new treatments, diagnostics, and cures; (3) fewer hurdles between research and new treatments; and (4) patient-centric approaches to drug discovery and development.